Drug intelligence / Profile preview

cerebral dopamine neurotrophic factor

Development stage
Phase 2
Lead developer
Herantis Pharma
Modality
Recombinant Proteins and Enzymes
Administration
Intracerebral
01

Overview

Cerebral dopamine neurotrophic factor (CDNF) is a protein-based, unconventional neurotrophic factor belonging to the CDNF/mesencephalic astrocyte-derived neurotrophic MANF family. It is primarily expressed in neurons and has potent neuroprotective and neurorestorative effects on midbrain dopaminergic neurons. Unlike classical neurotrophic factors, CDNF functions both as an extracellular trophic factor and as an intracellular endoplasmic reticulum (ER) luminal protein that protects cells against ER stress-induced apoptosis. Mechanistically, it regulates ER stress-induced unfolded protein response signaling and promotes protein homeostasis in the ER. CDNF has shown efficacy in protecting and repairing dopamine neurons in animal models of Parkinson's disease (PD), reducing α-synuclein aggregation, and alleviating behavioral deficits associated with PD models. Clinical trials have demonstrated its safety and tolerability for PD patients[1][3][4][6].

Other names
recombinant human cerebral dopamine neurotrophic factor
02

Targets

HSPA5 (Heat shock protein family A member 5)

Beyond the preview

Go deeper on cerebral dopamine neurotrophic factor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cerebral dopamine neurotrophic factor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call